Kamile Kırca1, Sevinç Kutlutürkan2. 1. Department of Nursing, Kırıkkale University School of Health Sciences, Kırıkkale, Turkey. 2. Department of Nursing, Gazi University School of Health Sciences, Ankara, Turkey.
Abstract
OBJECTIVE: The aim of this study is to evaluate the symptoms experience and quality of life in patients with breast cancer receiving the taxane class of drugs. MATERIALS AND METHODS: This study was performed between November 2015 March 2016 in a chemotherapy unit of a university hospital with 48 patients, who agreed to participate in the study. The Memorial Symptom Rating Score (MSAS), Socio-demographic and Clinical Features Form, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast (EORTC QLQ- BR23) measures specific to breast cancer were used to obtain data. RESULTS: The average age of the patients was 45.65. The majority of patients were treated with the paclitaxel/paclitaxel+trastuzumab treatment protocol (60.42%), and more than half (54.16%) of these patients were on 5 or 6 treatments. The symptoms patients experienced the most commonly included being sensitive, weakness or energy loss and pain. The symptoms they experienced severely were included fatigue and energy loss and being sensitive. The most distressing symptoms were pain, worry, numbness in hands and feet. The overall well-being score of the patients as per the quality of life findings was 46.18±11.66. While the lowest score for the functional scales was in the social function subscale (66.32±15.18), the highest score for the symptom scales was in the pain subscale (42.01±15.37). The lowest score for the EORTC QLQ-BR23 scales was in the sexual life subscale (20.83±20.19); the highest score was in the body appearance subscale (65.8±23.96). CONCLUSION: The results of the study are thought to be helpful for the oncology nurses in evaluating the patients in all aspects and in determining priorities for care.
OBJECTIVE: The aim of this study is to evaluate the symptoms experience and quality of life in patients with breast cancer receiving the taxane class of drugs. MATERIALS AND METHODS: This study was performed between November 2015 March 2016 in a chemotherapy unit of a university hospital with 48 patients, who agreed to participate in the study. The Memorial Symptom Rating Score (MSAS), Socio-demographic and Clinical Features Form, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast (EORTC QLQ- BR23) measures specific to breast cancer were used to obtain data. RESULTS: The average age of the patients was 45.65. The majority of patients were treated with the paclitaxel/paclitaxel+trastuzumab treatment protocol (60.42%), and more than half (54.16%) of these patients were on 5 or 6 treatments. The symptoms patients experienced the most commonly included being sensitive, weakness or energy loss and pain. The symptoms they experienced severely were included fatigue and energy loss and being sensitive. The most distressing symptoms were pain, worry, numbness in hands and feet. The overall well-being score of the patients as per the quality of life findings was 46.18±11.66. While the lowest score for the functional scales was in the social function subscale (66.32±15.18), the highest score for the symptom scales was in the pain subscale (42.01±15.37). The lowest score for the EORTC QLQ-BR23 scales was in the sexual life subscale (20.83±20.19); the highest score was in the body appearance subscale (65.8±23.96). CONCLUSION: The results of the study are thought to be helpful for the oncology nurses in evaluating the patients in all aspects and in determining priorities for care.
Entities:
Keywords:
Breast cancer; quality of life; symptom; taxane
Authors: Mary Ellen Haisfield-Wolfe; Deborah B McGuire; Karen Soeken; Jeanne Geiger-Brown; Bruce De Forge; Mohan Suntharalingam Journal: Support Care Cancer Date: 2011-10-04 Impact factor: 3.603
Authors: S Erensoy; A A Sayiner; S Türkoğlu; D Canatan; U S Akarca; R Sertöz; T Ozacar; Y Batur; S Badur; A Bilgiç Journal: Infection Date: 2002-10 Impact factor: 3.553
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: James L Khatcheressian; Patricia Hurley; Elissa Bantug; Laura J Esserman; Eva Grunfeld; Francine Halberg; Alexander Hantel; N Lynn Henry; Hyman B Muss; Thomas J Smith; Victor G Vogel; Antonio C Wolff; Mark R Somerfield; Nancy E Davidson Journal: J Clin Oncol Date: 2012-11-05 Impact factor: 44.544
Authors: Shoshana M Rosenberg; Rulla M Tamimi; Shari Gelber; Kathryn J Ruddy; Sandra Kereakoglow; Virginia F Borges; Steven E Come; Lidia Schapira; Eric P Winer; Ann H Partridge Journal: Psychooncology Date: 2012-11-07 Impact factor: 3.894
Authors: Susan Storey; Andrea Cohee; Diane Von Ah; Eric Vachon; Noah R Zanville; Patrick O Monahan; Timothy E Stump; Victoria L Champion Journal: J Patient Cent Res Rev Date: 2020-10-23